IL17A and depressive symptom measurement: A study analyzing the efficacy of 3 randomized, double-blind, controlled trials in patients with moderate-to-severe plaque psoriasis, found that ixekizumab, an anti-IL-17 antibody, reduced scores on the QIDS-SR-16 and improved depression at week 12.